Keyword: Karyopharm Therapeutics
Karyopharm took a 15% dip as investors waited for a phase 2b update on selinexor in refractory multiple myeloma.
Biogen is paying $10 million upfront and committing to up to $207 million more in milestones to buy the IND-ready oral SINE compound.
Embattled biotech Karyopharm is looking to move past its recent trial setbacks, penning an expansion to its original 2014 partnership on machine-learning tech and risk-based monitoring techniques for its cancer tests.
Karyopharm has seen studies for its big hope selinexor placed on a partial clinical hold, meaning it can no longer recruit new patients, over the FDA’s demands for more safety details, but the company insists this is all down to paperwork errors.
A phase 2 trial of Karyopharm’s selinexor in patients with acute myeloid leukemia (AML) has been deemed destined to fail during an interim analysis.